Market Currents
BioCryst Pharmaceuticals (BCRX) soars 16.4% in premarket trading after reporting favorable...
-
Wednesday, February 15, 2012, 8:16 AM ETBioCryst Pharmaceuticals (BCRX) soars 16.4% in premarket trading after reporting favorable results on testing of its hepatitis C treatment BCX5191. The preclinical study showed that BCX5191 demonstrates high oral bioavailability and is actively transported into the liver.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
